MLTX

The past six months have seen significant volatility in MoonLake Immunotherapeutics' stock, with a 75.04% decrease over the last year as of September 2026, and a 52-week range between $5.95 and $62.75. Key events include a mid-June 2026 rally following the announcement of year-long hidradenitis suppurativa data. In June 2026, the company completed a public offering of Class A shares, raising $189.8 million in net proceeds. In August 2026, positive topline results from its Phase 3 IZAR-1 trial of Sonelokimab in psoriatic arthritis were announced, demonstrating significant improvements across all clinical endpoints, though this still triggered a premarket sell-off. MoonLake plans to submit its Biologics License Application (BLA) for adult and adolescent hidradenitis suppurativa by the end of September 2026, with FDA acceptance and a potential Priority Review decision anticipated by late November 2026.